Compare Liquidia Corporation Common Stock (LQDA) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liquidia Corporation Common Stock vs SOLAI Limited — how do they compare? Liquidia Corporation Common Stock trades at $33.47 (market cap $3.04B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: Liquidia Corporation Common Stock is far larger — about 3.5× SOLAI Limited's market cap, and Liquidia Corporation Common Stock is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and SOLAI Limited for 42 Days on average.
| LQDA | SLAI | |
|---|---|---|
Market Cap | $3.04B | $880.09M |
Volume | 21,111,778 | 122,720 |
Sector | Health | Technology |
52-Week High | $91.03 | $21.63 |
52-Week Low | $22.02 | $2.74 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $2.94B | $879.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SOLAI Limited (SLAI) trades at $3.72 with no recent price movement, showing a mixed technical picture despite a bullish signal from indicators. The company faces severe financial distress with negative gross and net income margins, though it recently beat Q2 2025 EPS expectations. Recent developments include an extraordinary general meeting and a NYSE delisting notice, creating significant uncertainty for investors.
The outlook remains highly speculative with substantial execution and regulatory risks. While technical indicators suggest potential upside, fundamental weaknesses and delisting proceedings present clear downside risks. Investors should approach with caution given the company's negative profitability and ongoing corporate challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
